RAN-LABEL
  • RAN-MONTELUKAST is transitioning to TARO-MONTELUKAST; product with the new TARO label will be available in 2021. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change. click here

  • RAN-AMLODIPINE is transitioning to TARO-AMLODIPINE; product with the new TARO label will be available in 2021. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change. click here

  • RAN-CYPROTERONE/ETHINYL ESTRADIOL is transitioning to TARO-CYPROTERONE/ETHINYL ESTRADIOL; product with the new TARO label will be available in 2020. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change. click here

  • RAN-PRAVASTATIN is transitioning to TARO-PRAVASTATIN; product with the new TARO label will be available in 2020. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change.click here

  • RAN-RABEPRAZOLE is transitioning to TARO-RABEPRAZOLE; product with the new TARO label will be available in 2020. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change. click here

  • RAN-CLOPIDOGREL is transitioning to TARO-CLOPIDOGREL; product with the new TARO label will be available in 2020. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change. click here

  • RAN-GABAPENTIN is transitioning to TARO-GABAPENTIN; product with the new TARO label will be available in 2020. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change. click here

  • RAN-ZOPICLONE is transitioning to TARO-ZOPICLONE; product with the new TARO label will be available in 2020. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change. click here

  • RAN-PREGABALIN is transitioning to TARO-PREGABALIN; product with the new TARO label will be available in 2020. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change.click here

  • RAN-VENLAFAXINE XR is transitioning to TARO-VENLAFAXINE XR; product with the new TARO label will be available in 2020. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change.click here

  • RAN-CANDESARTAN is transitioning to TARO-CANDESARTAN; product with the new TARO label will be available in 2020. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change.click here

  • RAN-CIPROFLOX is transitioning to TARO-CIPROFLOX; product with the new TARO label will be available in 2020. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change. click here

  • RAN-DONEPEZIL is transitioning to TARO-DONEPEZIL; product with the new TARO label will be available in 2020. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change. click here

  • RAN-GLICLAZIDE MR is transitioning to TARO-GLICLAZIDE MR; product with the new TARO label will be available in 2020. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change.click here

  • RAN-IRBESARTAN is transitioning to TARO-IRBESARTAN; product with the new TARO label will be available in 2020. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change.click here

  • RAN-VALSARTAN is transitioning to TARO-VALSARTAN; product with the new TARO label will be available in 2020. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change. click here

  • RAN-LANSOPRAZOLE is transitioning to TARO-LANSOPRAZOLE; product with the new TARO label will be available in 2020. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change. click here

  • RAN-RAMIPRIL is transitioning to TARO-RAMIPRIL; product with the new TARO label will be available early in 2020. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change. click here

  • RAN-ATENOLOL is transitioning to TARO-ATENOLOL; product with the new TARO label will be available in 2020. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change.click here

  • RAN-BUPROPION XL is transitioning to TARO-BUPROPION XL; product with the new TARO label will be available early in 2020. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change. click here

  • RAN-CEFPROZIL is transitioning to TARO-CEFPROZIL; product with the new TARO label will be available early in 2020. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change. click here

  • RAN-RAMIPRIL HCTZ is transitioning to TARO-RAMIPRIL HCTZ; product with the new TARO label will be available early in 2020. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change click here

  • RAN-SIMVASTATIN is transitioning to TARO-SIMVASTATIN; product with the new TARO label will be available in 2020. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change. click here

  • RAN-ATORVASTATIN is transitioning to TARO-ATORVASTATIN; product with the new TARO label will be available early in 2020. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change. click here

  • RAN-CEFPROZIL ORAL SUSPENSION is transitioning to TARO-CEFPROZIL ORAL SUSPENSION; product with the new TARO label will be available early in 2020. For this product the DINs, UPCs and formulations will remain the same, only the prefix will change. click here

  • RAN-ROSUVASTATIN is transitioning to TARO-ROSUVASTATIN; product with the new TARO label will be available early in 2020. For this product the DINs will remain the same, however, the tablet formulation and appearance will change. Bottles of 90 will be replaced with bottles of 100 and UPCs will change. click here

  • RAN-SOLIFENACIN is transitioning to TARO-SOLIFENACIN; product with the new TARO label will be available early in 2020. For this product the DINs, UPCs, markings and formulations will remain the same, only the prefix will change. click here